Pharma and Biotech
Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -3.1% | 4.7% |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 2.0 | 1.9 |
Pr/Book | 1.2 |
Latest | F'cast | |
---|---|---|
Revenue | 7.5% | 6.6% |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-19 | 124.01 | (58.48) | (10.72)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-20 | 105.57 | (22.57) | (3.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-21 | 125.06 | (9.18) | (1.93)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-22 | 157.71 | (21.38) | (4.34)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-23 | 169.48 | (12.69) | (2.41)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-24 | 180.73 | 8.45 | (0.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-25 | 201.27 | 14.63 | 0.25p | 180.0 | n/a | n/a | n/a | 0.0% |
30-Sep-26 | 225.40 | 25.15 | 1.70p | 26.5 | 0.0 | +580% | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Form 8.5 (EPT/RI) - Benchmark Holdings Plc | 07-May-2024 | 08:51 | RNS |
Total Voting Rights | 02-May-2024 | 09:00 | RNS |
Form 8.5 (EPT/RI) - Benchmark Holdings Plc | 30-Apr-2024 | 10:55 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 45.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 48.00 |
52 Week Low | 34.00 |
Volume | 6,411 |
Shares Issued | 739.67m |
Market Cap | £332.85m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
08:10 | 6,411 @ 45.81p |
Chair | Peter George |
CFO | Septima Maguire |
CEO | Trond Williksen |
You are here: research